Gilead Sciences, Inc
Gilead Sciences, Inc를 보는 글로벌 시선
이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minKey HIV stat over 70% leaves BofA siding with Gilead
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fre…
원문 보기 ↗ YahooWhat Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
원문 보기 ↗ YahooGILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
원문 보기 ↗ YahooAmgen: The Market Is Underestimating Its Next Growth Phase
Amgen stock update: Tezspire and Repatha sales are surging as 2026 revenue guidance rises. Click here to read more about AMGN.
원문 보기 ↗ SeekingAlphaKYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
원문 보기 ↗ YahooGilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings
Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and raised guidance. Read more on GILD stock here.
원문 보기 ↗ SeekingAlphaMSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.
원문 보기 ↗ YahooKathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.
원문 보기 ↗ BenzingaCompass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...
Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
원문 보기 ↗ YahooKymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by …
원문 보기 ↗ YahooGilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.
원문 보기 ↗ YahooGilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation
AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while l…
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.